← Back to Search

Mono-morphemic Cluster PD for Speech Sound Disorder

N/A
Waitlist Available
Research Sponsored by San Diego State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change in percent consonant accuracy from baseline to immediately following final treatment session; up to 6 weeks.
Awards & highlights

Study Summary

This study is evaluating whether a specific type of therapy may help children with phonological disorder or specific language impairment.

Eligible Conditions
  • Speech Sound Disorder
  • Language Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change in percent consonant accuracy from baseline to immediately following final treatment session; up to 6 weeks.
This trial's timeline: 3 weeks for screening, Varies for treatment, and change in percent consonant accuracy from baseline to immediately following final treatment session; up to 6 weeks. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Generalization Probe Accuracy Change
Treatment Probe Accuracy Change

Trial Design

10Treatment groups
Experimental Treatment
Group I: Mono-morphemic Singleton PD-SLIExperimental Treatment1 Intervention
Speech sound treatment on mono-morphemic singleton consonants for children with PD-SLI.
Group II: Mono-morphemic Singleton PDExperimental Treatment1 Intervention
Speech sound treatment on mono-morphemic singleton consonants for children with PD.
Group III: Mono-morphemic Cluster PD-SLIExperimental Treatment1 Intervention
Speech sound treatment on mono-morphemic consonant clusters for children with PD-SLI.
Group IV: Mono-morphemic Cluster PDExperimental Treatment1 Intervention
Speech sound treatment on mono-morphemic consonant clusters for children with PD.
Group V: Bi-morphemic Singleton SLIExperimental Treatment2 Interventions
Treatment on singletons in bi-morphemic contexts for children with SLI.
Group VI: Bi-morphemic Singleton PD-SLIExperimental Treatment2 Interventions
Treatment on singletons in bi-morphemic contexts for children with PD-SLI.
Group VII: Bi-morphemic Singleton PDExperimental Treatment1 Intervention
Treatment on singletons in bi-morphemic contexts for children with PD.
Group VIII: Bi-morphemic Cluster SLIExperimental Treatment2 Interventions
Treatment on bi-morphemic consonant clusters for children with SLI.
Group IX: Bi-morphemic Cluster PD-SLIExperimental Treatment2 Interventions
Treatment on bi-morphemic consonant clusters for children with PD-SLI.
Group X: Bi-morphemic Cluster PDExperimental Treatment1 Intervention
Treatment on bi-morphemic consonant clusters for children with PD.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Morpheme treatment
2019
N/A
~50
Phonological treatment
2019
N/A
~50

Find a Location

Who is running the clinical trial?

National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
327 Previous Clinical Trials
178,174 Total Patients Enrolled
10 Trials studying Speech Sound Disorder
411 Patients Enrolled for Speech Sound Disorder
San Diego State UniversityLead Sponsor
150 Previous Clinical Trials
86,230 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Manipulating Linguistic Complexity to Improve Child Language Treatment Outcomes
Jessica Barlow 2019. "Manipulating Linguistic Complexity to Improve Child Language Treatment Outcomes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03977701.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top